Human papillomavirus testing 2007–2012: Co‐testing and triage utilization and impact on subsequent clinical management

In the United States, high‐risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC‐US) cytology, and co‐testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population‐based data are available...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2015-06, Vol.136 (12), p.2854-2863
Main Authors: Cuzick, Jack, Myers, Orrin, Hunt, William C., Saslow, Debbie, Castle, Philip E., Kinney, Walter, Waxman, Alan, Robertson, Michael, Wheeler, Cosette M.
Format: Article
Language:English
Subjects:
Adult
Aged
Cancer
Cellular biology
Cervical cancer
Cervical Intraepithelial Neoplasia - diagnosis
Cervical Intraepithelial Neoplasia - virology
cervical screening
coverage
Female
high‐risk HPV testing
HPV co‐testing
Human papillomavirus
Humans
Mass Screening - methods
Mass Screening - statistics & numerical data
Medical research
Medical screening
Middle Aged
New Mexico
New Mexico HPV Pap Registry
outcome
Papillomaviridae - isolation & purification
Papillomaviridae - physiology
Papillomavirus Infections - diagnosis
Papillomavirus Infections - virology
Patient Acceptance of Health Care - statistics & numerical data
Primary Health Care - trends
Primary Health Care - utilization
Registries - statistics & numerical data
United States
Uterine Cervical Neoplasms - diagnosis
Uterine Cervical Neoplasms - virology
utilization
Vaginal Smears - methods
Vaginal Smears - statistics & numerical data
Women
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the United States, high‐risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC‐US) cytology, and co‐testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population‐based data are available to examine utilization of HPV testing in the United States. Using the New Mexico HPV Pap Registry data resource, we describe population trends (2007–2012) in utilization and positivity rates for HPV testing as a routine co‐testing screening procedure and for triage of ASC‐US and other cytologic outcomes. For women aged 30–65 years co‐testing increased from 5.2% in 2007 to 19.1% in 2012 (p 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.29337